Bryan Garnier - Novo Nordisk (novob) NOVO NORDISK: Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable | NEUTRAL | DKK365 vs. DKK358 (+2%)

Report

Bryan Garnier

Eric Le Berrigaud

NOVO NORDISK: Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable | NEUTRAL | DKK365 vs. DKK358 (+2%)

NOVO NORDISK - NEUTRAL | DKK365 vs. DKK358 (+2%)
Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable

Rybelsus carries the same label as injectable GLP1s
Instructions for administration to be more cumbersome
Novo-Nordisk has to position it right into the portfolio

23/09/2019 3 EN

Underlying

Novo Nordisk

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

New Street Research

Novo - EVOKE Clouds 18% Sales D/G Risk (HOLD, TP DKK 300, 17pgs)

For access to the full note, please contact Naresh Chouhan ( )

EUR 4303.50

October 7, 2025 October 7, 2025 1 EN

New Street Research

Novo - Upgrade to HOLD (PT DKK300, 8pgs)

With the orfo’ data being on the lower side of expectations, we upgrade to Hold as the narrative is likely to be dominated by the potential upside for Novo. However, we remain convinced that: 1) The obesity market is nowhere near as big as the market believes, 2) Ozempic no’s are far too high & 3) Margin forecasts need to fall. Cons’ Ozempic forecasts will take time to fall & we will likely need the IRA price in November to force consensus lower. Therefore, we see limited S-T downside to our DKK300 PT. In upcoming research, we will show why the obesity market is materially smaller than expecta...

EUR 4303.50

August 8, 2025 August 8, 2025 1 EN

New Street Research

Novo - Oversize Downgrade - PT Cut to DKK300 (SELL, TP DKK300 [350], 8pgs)

Whilst our downgrade to Sell [here] was predicated on reduced Ozempic sales & significantly below cons. forecasts, the magnitude of the ’25 profit warning has led to a material reset of our forecasts & we are now >30% below cons. EBIT in 2029. We expect the debate to now focus on valuation given we model just 5% 25-30 CAGR sales growth & sema accounts for 60% of 2030 EBIT. Worryingly, our EPS declines in 2027 having cut our sales forecasts by 4-9% & EBIT forecasts by 6%-13%. We are now 27% below 2027 cons. EPS (pre-warning). Given the lacklustre growth of both the diabetes & obesity markets, w...

EUR 4303.50

July 30, 2025 July 30, 2025 1 EN

Discontinuing Coverage Ahead of Stifel Integration

On June 2, 2025, Stifel Financial Corporation acquired Bryan, Garnier & Co Limited and Bryan Garnier Securities, which have been rebranded to Stifel Europe Limited and Stifel Europe Securities, respectively. Today, August 22, 2025, both entities are being integrated into the Stifel research pla

August 22, 2025 August 22, 2025 1 EN

Stifel Europe Limited Research

Stifel Europe Limited Research

Discontinuing Coverage

We are discontinuing coverage of the companies listed in the chart below. Our past recommendations on these names should no longer be relied upon.

August 21, 2025 August 21, 2025 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Alfen: H1 2025 results, mid-term outlook lowered

Alfen published H1 2025 figures yesterday. Revenue came in at EUR211.5m (-13.9% YoY vs. EUR245.7m in H1 2024) mainly with challenging dynamics in EV charging and Energy Storage, while benefiting from favourable base effects in Smart Grids, which was impacted by moistening issues in Q2 2024. This wa

August 21, 2025 August 21, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO NORDISK: Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable | NEUTRAL | DKK365 vs. DKK358 (+2%)

Novo - EVOKE Clouds 18% Sales D/G Risk (HOLD, TP DKK 300, 17pgs)

Novo - Upgrade to HOLD (PT DKK300, 8pgs)

Novo - Oversize Downgrade - PT Cut to DKK300 (SELL, TP DKK300 [350], 8pgs)

Discontinuing Coverage Ahead of Stifel Integration

Discontinuing Coverage

Alfen: H1 2025 results, mid-term outlook lowered

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe